Related Experiment Video
Updated: May 26, 2026
08:34
Robot-assisted Partial Splenectomy
Published on: January 2, 2026
A comparative cost analysis of robot-assisted versus traditional laparoscopic partial nephrectomy
Elias Hyams1, Philip Pierorazio, Jeffrey K Mullins
1James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21230, USA. eliash99@hotmail.com
Journal of Endourology
|December 30, 2011
Summary
Robot-assisted partial nephrectomy (RPN) costs more than traditional laparoscopic partial nephrectomy (LPN), but higher robotic utilization significantly reduces the cost difference. Optimizing robot use is key to making RPN more cost-effective.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Health Economics
Background:
- Robot-assisted laparoscopic partial nephrectomy (RALPN) is increasingly adopted over traditional laparoscopic partial nephrectomy (LPN).
- Adoption is driven by perceived clinical benefits and patient demand.
- Cost implications of RALPN require thorough investigation.
Purpose of the Study:
- To quantify the cost difference between RALPN and LPN.
- To analyze the impact of robotic utilization on cost-effectiveness.
Main Methods:
- A cost analysis compared 20 RALPN and 20 LPN cases.
- Included perioperative, hospitalization, and professional fees.
- Capital costs were estimated based on system purchase, amortization, and maintenance, with analyses for actual and ideal robotic utilization.
Main Results:
- RALPN incurred an average cost premium of $1066 per case compared to LPN with actual robot utilization.
- With assumed ideal utilization, the premium decreased to $334 per case.
- Capital costs per case decreased from $1907 to $1175 with ideal utilization; tumor size, operative time, and length of stay were similar between groups.
Conclusions:
- RALPN presents a moderate cost premium, influenced by robotic surgical volume.
- Maximizing robotic system utilization reduces associated capital costs, improving cost-competitiveness with LPN.
- Further research into the clinical benefits of RALPN is needed to understand their potential cost implications.
